Acute Myeloid Leukaemia (AML) is a haematologic malignancy. Despite of improvements in prognosis it is still a severe disease and only a minority of patients are cured. Recently, insights into specific cytogenetics and biological aberration involved in the leukaemogenesis process are the target of research. LAM-99P GIMEMA Protocol identifies treatment guidelines for AML in adults. A methodological approach is proposed, compounding different modelling techniques, to assess the prognostic relevance of clinical as well as biological markers with regard to clinical endpoint, such as the achievement of Complete Remission in the short-term and long-term survival taking into account competing risks.
Evaluation of short- and long-term response to treatment in GIMEMA protocol for Acute Myeloid Leukaemia / I. Ardoino, F. Ambrogi, S. Iacobelli, P. Boracchi, G. Manikis, M.G. Kounelakis, M. Zervakis, P.J.G. Lisboa, P. Fazi, M. Vignetti, E. Biganzoli, A. Starita. - In: INTERNATIONAL JOURNAL OF BIOMEDICAL ENGINEERING AND TECHNOLOGY. - ISSN 1752-6418. - 3:3/4(2010), pp. 329-348.
|Titolo:||Evaluation of short- and long-term response to treatment in GIMEMA protocol for Acute Myeloid Leukaemia|
ARDOINO, ILARIA (Primo)
AMBROGI, FEDERICO (Secondo)
BIGANZOLI, ELIA (Penultimo)
|Parole Chiave:||Acute myeloid leukaemia; AML; Competing risks; CR; Multinomial logistic regression; Support vector machines; Survival analysis|
|Settore Scientifico Disciplinare:||Settore MED/01 - Statistica Medica|
Settore MED/06 - Oncologia Medica
|Data di pubblicazione:||2010|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1504/IJBET.2010.032699|
|Appare nelle tipologie:||01 - Articolo su periodico|